Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - SINO BIOPHARMACEUTICAL S&P ESG RATING GETS ANOTHER UPGRADE RANKING TOP 9% IN THE GLOBE2023.12.11
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.12.08
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.12.07
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.12.06
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.12.05
-
VOLUNTARY ANNOUNCEMENT - FIRST DOSE OF THE FIRST BATCH OF SUBJECTS IN PHASE I CLINICAL TRIAL OF TQA3038 "siRNA" COMPLETED2023.12.05
-
VOLUNTARY ANNUONCEMENT - SINO BIOPHARMACEUTICAL AWARDED "2023 FORBES CHINA ESG INNOVATIVE ENTERPRISE"2023.12.04
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 20232023.12.01